Beaten-down UK stocks set for a big bounce
UK stocks shrugged off this week’s new lockdown. And provided the vaccination campaign goes ahead smoothly, traders will remain bullish.
“The darkest hour is just before the dawn,” says Rupert Thompson of Kingswood. British shares shrugged off this week’s new lockdown, with the FTSE 100 gaining almost 2% in the first two days of the year. The short-term news is dire, but investors are concentrating on the vaccine rollout, which should pave the way for a return to normal. Provided the vaccination campaign continues without any serious glitches then traders will remain bullish.
The Brexit deal was met with relief. With no-deal uncertainty finally out of the way another key headwind has been removed for UK shares. The index has plenty of room to rise after turning in an abysmal performance last year, falling by 14.3% for its worst showing since 2008. The FTSE 100 has underperformed for some time, notes Stefan Wagstyl in the Financial Times. Since 2016 it has gained less than 8%, compared with a 44% rise in German markets. British shares finally picked up in October, with the FTSE 250 up by 22% since then. That isn’t just vaccine euphoria. It also reflects hope that with the post-Brexit outlook clearer business investment will soar.
There are other reasons for cautious optimism about 2021, says David Smith in The Sunday Times. Powered by Asian dynamism, the global economy will provide a benign backdrop this year. British consumers have amassed huge involuntary savings, which are likely to spark a spending boom.
MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Unemployment should peak at a lower level than during previous downturns thanks to the furlough scheme. A brighter profits outlook could spark new interest in UK equities. As Stephen Innes of Axi points out, valuations are currently “close to 20-year lows” compared with Europe. Our “beaten-down” stocks could be “set for a magnificent recovery”.
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
Alex is an investment writer who has been contributing to MoneyWeek since 2015. He has been the magazine’s markets editor since 2019.
Alex has a passion for demystifying the often arcane world of finance for a general readership. While financial media tends to focus compulsively on the latest trend, the best opportunities can lie forgotten elsewhere.
He is especially interested in European equities – where his fluent French helps him to cover the continent’s largest bourse – and emerging markets, where his experience living in Beijing, and conversational Chinese, prove useful.
Hailing from Leeds, he studied Philosophy, Politics and Economics at the University of Oxford. He also holds a Master of Public Health from the University of Manchester.
-
HMRC stamp duty crackdown sees probes of property deals jump 88% – what to watch out forFrom bogus stamp duty refund claims to misleading the taxman about who owns a property, HMRC is increasing its scrutiny of stamp duty land tax reporting. Here’s how.
-
The UK areas which saw biggest jump in asking prices in 2025 – is yours on the list?We look at the UK areas where asking prices rose the most last year.
-
Three promising emerging-market stocks to diversify your portfolioOpinion Omar Negyal, portfolio manager, JPMorgan Global Emerging Markets Income Trust, highlights three emerging-market stocks where he’d put his money
-
Coface offers excess profit in an unloved sectorCoface is a world leader in trade-credit insurance with key competitive advantages in a niche market
-
Exciting opportunities in biotechBiotech firms should profit from the ‘patent cliff’, which will force big pharmaceutical companies to innovate or make acquisitions
-
How to invest in the new breed of payment providersUpstart payment providers are taking the world by storm. It’s time for investors to buy in, says Rupert Hargreaves
-
What turns a stock market crash into a financial crisis?Opinion Professor Linda Yueh's popular book on major stock market crashes misses key lessons, says Max King
-
How to add cryptocurrency to your portfolioA new listing shows how bitcoin might add value to a portfolio if cryptocurrency keeps gaining acceptance, says Cris Sholto Heaton
-
Profit from pest control with Rentokil InitialRentokil Initial is set for global expansion and offers strong sales growth
-
Three funds to buy for capital growth and global incomeOpinion Three investment trusts with potential for capital growth, selected by Adam Norris, co-portfolio manager of the CT Global Managed Portfolio Trust